A novel concept of identifying precancerous cells to enhance anti-cancer therapies

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 19, Issue 6, 2012, Pages 621-625

  Zheng, Yun Wen ^a   Tsuchida, Tomonori ^a   Taniguchi, Hideki ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Cancer stem cells; Hepatocellular carcinoma; Precancerous cells; Target therapy

Indexed keywords

ACYCLIC RETINOID; ANTINEOPLASTIC AGENT; CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GLUTATHIONE TRANSFERASE; HERMES ANTIGEN; PLACEBO; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AWARENESS; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CANCER SCREENING; CANCER STEM CELL; CANCER THERAPY; CARCINOMA IN SITU; CELL DIFFERENTIATION; CELL EXPANSION; CELL FATE; CELL FUNCTION; CELL ISOLATION; CELL REGENERATION; CELL TRANSFORMATION; DRUG TARGETING; EARLY DIAGNOSIS; GENOMIC INSTABILITY; HUMAN; LIVER CARCINOGENESIS; LIVER CARCINOMA IN SITU; LIVER CELL CARCINOMA; LIVER OVAL CELL; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; NEOPLASM; NONHUMAN; PRECANCER; PRECANCER CELL; PROGENY; SOMATIC MUTATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; PRECANCEROUS CONDITIONS; TISSUE THERAPY;

EID: 84872201465     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-012-0546-2     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 (Internet). Lyon: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr (accessed on 16/5/2012).
2. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres- Cortes J, et al.Acell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645-8. doi:10.1038/367645a0. (Pubitemid 24067706)
3. Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology. 2007;133(3):937- 50. doi:10.1053/j.gastro.2007.06. 016.
4. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401. doi:10.1038/nature03128.
5. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003;100(25):15178-83. doi:10.1073/pnas. 2036535100.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE.A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106-10. doi:10.1038/nature05372.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer- initiating cells. Nature. 2007;445(7123):111-5. doi:10.1038/ nature05384. (Pubitemid 46067311)
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983-8. doi:10.1073/pnas. 05302911000530291100. (Pubitemid 36418143)
9. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555-67. doi:10.1016/j.stem. 2007.08.014.
10. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946-51. doi:10.1158/0008-5472. CAN-05-2018.
11. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44? prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25(12):1696-708. doi: 10.1038/sj.onc.1209327.
12. FangD, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, et al.A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65(20):9328-37. doi:10.1158/0008-5472.CAN- 05-1343.
13. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, et al. Identification of cells initiating human melanomas. Nature. 2008;451(7176):345-9. doi:10.1038/nature 06489.
14. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313-23. doi:10.1016/j.stem. 2007.06.002.
15. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030-7. doi:10.1158/0008-5472.CAN-06-2030.
16. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44(1):240-51. doi:10.1002/hep.21227.
17. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007;120(7):1444-50. doi:10.1002/ijc. 22476.
18. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/ progenitor cells. Gastroenterology. 2007;132(7):2542-56. doi: 10.1053/j.gastro.2007.04.025.
19. Braun L, Mikumo R, Fausto N. Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation. Cancer Res. 1989;49:1554-61.
20. Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis. 2002;23:435-45.
21. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431(7012):1112-7. (Pubitemid 39472236)
22. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006; 12(4):410-6.
23. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, et al. Cancer stem/ progenitor cells are highly enriched in CD133?CD44?population in hepatocellular carcinoma. Int J Cancer. 2010;126(9):2067-78. doi:10.1002/ijc.24868.
24. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 2008;99(1):100-9. doi:10.1038/sj.bjc.6604437. (Pubitemid 351920235)
25. Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47(3):919-28. doi:10.1002/hep.22082.
26. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27(5):1006-20. doi: 10.1002/stem.30.
27. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, et al. Wnt/betacatenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 2008;68(11):4287-95. doi: 10.1158/0008-5472.CAN-07-6691.
28. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumorinitiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012-24. doi:10.1053/j.gastro.2008.12.004.
29. Suzuki A, Sekiya S, Onishi M, Oshima N, Kiyonari H, Nakauchi H, et al. Flow cytometric isolation and clonal identification of self-renewing bipotent hepatic progenitor cells in adult mouse liver. Hepatology. 2008;48(6):1964-78. doi:10.1002/hep.22558.
30. Yovchev MI, Grozdanov PN, Zhou H, Racherla H, Guha C, Dabeva MD. Identification of adult hepatic progenitor cells capable of repopulating injured rat liver. Hepatology. 2008;47(2):636-47. doi:10.1002/hep.22047.
31. Yin L, Sun M, Ilic Z, Leffert HL, Sell S. Derivation, characterization, and phenotypic variation of hepatic progenitor cell lines isolated from adult rats. Hepatology. 2002;35(2):315-24. doi: 10.1053/jhep.2002.31355.
32. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev. 2003;120(1):117- 30. pii: S0925477302003386. (Pubitemid 35462100)
33. Andersen JB, Loi R, Perra A, Factor VM, Ledda-Columbano GM, Columbano A, et al. Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology. 2010;51(4):1401-9. doi: 10.1002/hep.23488.
34. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol. 1999;154(2):537-41. doi: 10.1016/S0002-9440(10)65299-6.
35. Satoh K, Kitahara A, Soma Y, Inaba Y, Hatayama I, Sato K. Purification, induction, and distribution of placental glutathione transferase: a new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. Proc Natl Acad Sci USA. 1985;82(12):3964-8. (Pubitemid 15052809)
36. Ogiso T, Tatematsu M, Tamano S, Tsuda H, Ito N. Comparative effects of carcinogens on the induction of placental glutathione S-transferase-positive liver nodules in a short-term assay and of hepatocellular carcinomas in a long-term assay. Toxicol Pathol. 1985;13(4):257-65.
37. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996;334(24):1561-7. doi:10.1056/NEJM199606133342402. (Pubitemid 26177483)
38. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med. 1999;340(13):1046-7. doi:10.1056/NEJM1999 04013401315. (Pubitemid 29157643)
39. Okusaka T, Makuuchi M, Matsui O, Kumada H, Tanaka K, Kaneko S, et al. Clinical benefit of peretinoin for the suppression of hepatocellular carcinoma (HCC) recurrence in patients with Child-Pugh grade A (CP-A) and small tumor: a subgroup analysis in a phase II/III randomized, placebo-controlled trial. J Clin Oncol. 2011;29(suppl 4; abstr 165).